Research Article
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
Table 1
Distribution of patients according to baseline characteristics.
| | Baseline characteristics | New diagnosis | Recurrent | | Nimo + CT + RT (n = 44) | Nimo + CT (n = 21) | Nimo + RT (n = 14) | Nimo (n = 21) | Nimo + CT (n = 5) | Nimo (n = 6) | | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) |
| | Gender | Male | 40 (89.9) | 17 (85.0) | 13 (92.9) | 17 (81.0) | 5 (100) | 6 (100) | | Female | 5 (11.1) | 3 (15.0) | 1 (7.1) | 4 (19.0) | — | — |
| | Age | Mean ± SD | 63.9 ± 6.8 | 60.5 ± 13.2 | 60.9 ± 9.6 | 61.9 ± 7.6 | 56.4 ± 5.9 | 64.1 ± 8.2 | | Median ± R | 64 ± 10 | 57 ± 23 | 62 ± 15 | 61.0 ± 11 | 56 ± 11 | 67.0 ± 16 | | (Mín; máx) | (48; 77) | (42; 86) | (47; 76) | (49; 76) | (49; 64) | (53; 75) |
| | Smoking | Nonsmoker | 5 (11.1) | 3 (15.0) | 2 (14.3) | 2 (9.5) | — | — | | Ex-smoker | 10 (22.2) | 2 (10.0) | 5 (35.7) | 6 (28.6) | 1 (20.0) | 2 (33.4) | | Smoker | 30 (66.7) | 15 (75.0) | 7 (50.0) | 13 (61.9) | 4 (80.0) | 4 (66.6) |
| | Alcoholism | Yes | 37 (82.2) | 15 (75.0) | 11 (78.6) | 16 (76.2) | 3 (60.0) | 3 (50.0) | | No | 8 (17.8) | 5 (15.0) | 3 (21.4) | 5 (23.8) | 2 (40.0) | 3 (50.0) |
| | Tumor location | Cervical portion | 3 (6.8) | 3 (14.3) | 1 (7.1) | 1 (4.8) | — | — | | Intrathoracic upper | 6 (13.6) | 5 (23.8) | 4 (28.6) | 3 (14.3) | — | — | | Intrathoracic middle | 33 (75.0) | 11 (52.4) | 9 (64.3) | 15 (71.4) | 4 (80.0) | 6 (100.0) | | Not available | 2 (4.5) | 2 (9.5) | — | 2 (9.5) | 1 (20.0) | — |
| | Clinical stage | Ia | 3 (6.8) | 1 (4.8) | — | — | — | — | | Ib | 1 (2.3) | 4 (19.0) | 1 (7.1) | — | 1 (20.0) | — | | IIa | 3 (6.8) | 2 (9.5) | 1 (7.1) | 1 (4.8) | — | — | | IIb | 4 (9.1) | 2 (9.5) | 1 (7.1) | 2 (9.5) | 1 (20.0) | — | | IIIa | 8 (18.2) | 1 (4.8) | 4 (28.6) | 4 (19.0) | — | 1 (16.7) | | IIIb | 14 (31.8) | 2 (9.5) | 5 (35.7) | 4 (19.0) | 1 (20.0) | 1 (16.7) | | IIIc | 1 (2.3) | 1 (4.8) | — | 1 (4.8) | — | 1 (16.7) | | IV | 8 (18.2) | 6 (28.6) | 2 (14.3) | 7 (33.3) | 2 (40.0) | 3 (50.0) | | Not available | 2 (9.5) | 2 (9.5) | — | 2 (9.5) | — | — |
|
|
Nimo: nimotuzumab, CT: chemotherapy, RT: radiotherapy, SD: standard deviation, R: range.
|
